English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Clinical outcomes in patients with invasive aspergillosis have significantly improved [1, 2]. This may, in part, be related to earlier diagnosis, leading to earlier institution of treatment and better tolerated, effective, and safe treatment options [2, 3]. The study of diagnostic and therapeutic modalities for invasive aspergillosis has been greatly facilitated by the introduction of definitions for invasive fungal infections established by the European Organization for Research and Treatment of Cancer and the Mycosis Study Group (EORTC-MSG) in 2002, which have recently been updated and published in this journal [4, 5]. On the basis of the EORTC-MSG definitions, an invasive fungal infection is considered to be proven (usually requiring tissue biopsy), probable, or possible. The presence of a microbiologic diagnosis in addition to host, clinical, and radiographic factors differentiates a probable from a possible invasive fungal infection [4, 5]. These def-

Chest Computed Tomography versus Serum Galactomannan Enzyme Immunoassay for the Diagnosis of Probable Invasive Aspergillosis: To Be Decided